Home Journals Articles Updates About
CN
image
收藏切换
Expansion of IL-2-independent tumor-infiltrating lymphocytes through a feeder-free process: a preclinical study for solid tumors
收藏切换
PDF
Ying Zhang1, Sicheng Du1, Rongrui Liu2, Chuanhua Zhao2, Juan Li2, Sisi Ye2, Man Zhang3, Xingming Ma3, Zhou He3, Wenjia Zhuang3, Huajun Jin3, Jianming Xu2
Cancer Biology & Medicine | 2026, 23(6) : 910 - 924
Less
收藏切换
Cancer Biology & Medicine | 2026, 23(6): 910-924
• Original Article •
Expansion of IL-2-independent tumor-infiltrating lymphocytes through a feeder-free process: a preclinical study for solid tumors
Full
Ying Zhang1, Sicheng Du1, Rongrui Liu2, Chuanhua Zhao2, Juan Li2, Sisi Ye2, Man Zhang3, Xingming Ma3, Zhou He3, Wenjia Zhuang3, Huajun Jin3, Jianming Xu2
Affiliations
  • 1Medical School of Chinese People’s Liberation Army (PLA) General Hospital, Beijing 100853, China
  • 2Senior Department of Oncology, Chinese PLA General Hospital, Beijing 100853, China
  • 3Shanghai Juncell Therapeutics, Shanghai 201802, China
About Author:

Author contributions

Conceptualization and study design: Huajun Jin, Jianming Xu.

Methodology and investigation: Ying Zhang, Sicheng Du, Rongrui Liu, Chuanhua Zhao, Juan Li, Sisi Ye, Man Zhang, Xingming Ma, Zhou He, Wenjia Zhuang.

Data curation: Ying Zhang, Man Zhang, Xingming Ma, Zhou He, Wenjia Zhuang.

Technical support: Huajun Jin.

Project administration: Huajun Jin, Jianming Xu.

Funding acquisition: Huajun Jin.

Supervision: Huajun Jin, Jianming Xu.

Data analysis: Ying Zhang and Wenjia Zhuang.

Writing—original draft: Ying Zhang and Wenjia Zhuang.

Writing—review & editing: All authors.

Published: 2026-06-15 doi: 10.20892/j.issn.2095-3941.2025.0441
Outline
收藏切换
Objective:

Conventional tumor-infiltrating lymphocyte (TIL) therapy for solid tumors relies on high-dose interleukin-2 (IL-2) during expansion and post-infusion, and promotes T-cell exhaustion and toxicity. Herein, we developed a feeder-free, low-dose IL-2 TIL expansion protocol and evaluated whether hydroxychloroquine (HCQ) or programmed cell death protein 1 (PD-1) blockade might enhance therapeutic efficacy and decrease IL-2 dependence.

Methods:

TILs from multiple solid tumors were expanded ex vivo with decreased-dose IL-2, IL-7, and IL-15 plus CD3/CD28 co-stimulation, without feeder cells. TIL products were assessed via quality control, T-cell phenotypes, and exhaustion markers. Cytotoxic activity was measured in vitro through interferon-gamma (IFN-γ) release and real-time cell analysis (RTCA). HCQ-induced changes in major histocompatibility complex class I (MHC-I) and programmed death-ligand 1 (PD-L1) expression were assessed in tumor cell lines, and RTCA-based cytotoxicity was evaluated using T-cell receptor–engineered T cells (TCR-T cells). The in vivo efficacy of HCQ and PD-1 blockade separately combined with TIL therapy was examined in a colorectal cancer patient-derived xenograft (PDX) model.

Results:

The protocol consistently produced viable TILs of favorable quality across tumor types, with variable CD8+ and memory T-cell profiles. Expanded TILs showed effector-to-target (E:T) ratio-dependent tumor cell killing in RTCA and secreted IFN-γ across multiple tumor types. HCQ significantly upregulated MHC-I expression in vitro (P < 0.05) without affecting PD-L1 expression or impairing TIL proliferation, and enhanced early TCR-T–mediated killing. In the PDX model, TIL plus HCQ, compared with TIL, showed less tumor growth and greater MHC-I expression, although these differences were not significant, given the small sample size. TIL plus low-dose PD-1 blockade significantly reduced tumor volume versus the control group (P = 0.002) and maintained higher body weights than the TIL-only and control groups.

Conclusions:

The feasibility of a feeder-free, low-dose IL-2 TIL expansion system was demonstrated. PD-1 blockade significantly enhanced antitumor activity and treatment tolerability, thus supporting its promise as an alternative to high-dose IL-2. HCQ demonstrated potential immunomodulatory effects, although its in vivo benefit was minimal. This strategy warrants further clinical evaluation in solid tumors.

Tumor-infiltrating lymphocytes  /  solid tumors  /  PD-1 blockade  /  hydroxychloroquine  /  MHC class I
Ying Zhang, Sicheng Du, Rongrui Liu, Chuanhua Zhao, Juan Li, Sisi Ye, Man Zhang, Xingming Ma, Zhou He, Wenjia Zhuang, Huajun Jin, Jianming Xu. Expansion of IL-2-independent tumor-infiltrating lymphocytes through a feeder-free process: a preclinical study for solid tumors[J]. Cancer Biology & Medicine, 2026 , 23 (6) : 910 -924 . DOI: 10.20892/j.issn.2095-3941.2025.0441
Full Text
Less
Introduction
Less
Adoptive cell therapy with tumor-infiltrating lymphocytes (TILs), a promising approach for solid tumors, uses polyclonal, tumor-reactive T cells isolated directly from tumor tissue1,2. Lifileucel’s recent Food and Drug Administration approval for advanced melanoma supports the clinical feasibility of this strategy3. However, conventional TIL expansion protocols rely on high-dose interleukin-2 (IL-2) and feeder cells, which promote T-cell exhaustion and complicate manufacturing4–6. Lymphodepleting chemotherapy and systemic high-dose IL-2 administration further increase toxicity risks and therefore limit broader clinical use7,8.
The young TIL approach was designed to shorten the culture duration and eliminate tumor-reactivity screening, thereby preserving less-differentiated T cells with improved in vivo persistence9,10. Nevertheless, high-dose IL-2 remains a risk factor for T-cell exhaustion11,12. Decreasing IL-2 levels while supplementing cells with IL-7 and IL-15 maintains expansion efficiency, promotes central memory T-cell (TCM) differentiation, and decreases regulatory T-cell induction13–15. Additionally, CD3/CD28 co-stimulation enhances activation and decreases activation-induced cell death16–19. Beyond intrinsic TIL optimization, targeting tumor-intrinsic immune escape and modulating the tumor microenvironment (TME) may further improve efficacy. Major histocompatibility complex class I (MHC-I) downregulation, a key immune escape mechanism in solid tumors, impairs CD8+ T-cell recognition20,21. Autophagy contributes to MHC-I degradation, whereas the autophagy inhibitor hydroxychloroquine (HCQ) can restore MHC-I expression and modulate antitumor immunity22–24. Programmed cell death protein 1 (PD-1) blockade offers an alternative to post-infusion IL-2 by reactivating exhausted T cells without associated toxicity. Notably, even low doses of high-affinity PD-1 blockade therapies, such as sintilimab, can achieve sufficient receptor occupancy for therapeutic effects25–28.
In this preclinical study, we developed a feeder-free, cytokine-optimized TIL expansion strategy using low-dose IL-2 during ex vivo expansion and subsequently investigated combination approaches with HCQ or low-dose PD-1 blockade to further decrease IL-2 dependence, thereby addressing the limitations of conventional TIL therapy and informing safer, more feasible treatment options for solid tumors.
Materials and methods
Less
TIL isolation and expansion
Tumor specimens were obtained from patients with melanoma (MM), pancreatic cancer (PC), gastric cancer (GC), cervical cancer (CxCa), or colorectal cancer (CRC). The study was approved by the Ethics Committee of the Chinese PLA General Hospital (Approval No. S2022-313-02), and informed consent was obtained from each participant before sample collection. Solid tumors were minced into small fragments and cultured in X-VIVO 15 medium supplemented with recombinant human IL-2 (2,000 IU/mL), IL-7 (10 ng/mL), and IL-15 (10 ng/mL) (all from R&D Systems) in the pre-rapid expansion protocol (pre-REP). After pre-REP culturing, TILs were transferred to the rapid expansion protocol (REP), seeded onto plates pre-coated with anti-CD3 (BioLegend) and anti-CD28 (R&D Systems), cultured for 2 days, and then transferred to G-REX100 for further expansion in REP culture medium containing X-VIVO 15 and rhIL-2 (300 IU/mL), as previously described29,30. The expansion success of TILs was based on the cell count; confirmation of an absence of tumor cells, mycoplasma, bacterial contamination, and tumorigenicity; and assessment of T-cell phenotypes and exhaustion markers. Cytotoxicity was evaluated through interferon-gamma (IFN-γ) secretion and real-time cytotoxicity assays. The final TIL products were cryopreserved in liquid nitrogen for subsequent analyses.
Quality control of expanded TILs
Cell counts were measured with acridine orange/propidium iodide (AO/PI) staining. Briefly, the cell suspensions were thoroughly mixed with 10 μL AO/PI staining solution (Countstar, cat. No. RE010212), loaded into disposable counting slides (Countstar, cat. No. C0010101), and analyzed with an automated cell counter (Countstar Rigel S2). Viable cells were identified as AO+/PI−. Other quality control measures included mycoplasma detection through real-time quantitative polymerase chain reaction with MycoSHENTEK DNA extraction and detection kits (cat. Nos. SK0801MY50 and SK0802MY50). Sterility testing was performed with rapid microbial methods and direct inoculation. The tumorigenicity of the final TIL products was assessed with agarose colony formation assays. All test results were confirmed to be negative.
Flow cytometry of TILs
To exclude any tumor cell contamination, we stained TILs with antibodies to CD45 (BioLegend, 304016), CD3 (BioLegend, 344804), and tumor-associated markers. Tumor cell positivity was defined as ≥ 0.01% of cells expressing any tumor marker, whereas negativity was confirmed in 3 independent replicates. For functional assessment, TILs (5 × 105 to 2 × 106 cells) were washed in DPBS and stained with fluorescent antibodies to CD45, CD3, CD4, CD8, CD45RO, and CD62L, and the immune exhaustion markers PD-1, CD39, and lymphocyte activation gene 3 (LAG-3) (all from BioLegend, cat. Nos. 304016, 344804, 317428, 344714, 304206, 304822, 367404, 328218, and 369304). After incubation for 20 min at room temperature in the dark, the cells were washed and analyzed with a CytoFLEX flow cytometer (Beckman Coulter). Data were gated on CD45+CD3+ lymphocytes. The frequency of PD-1, CD39, and LAG-3 was assessed within the CD3+ T-cell population to evaluate immune exhaustion across various cancer types. Memory T-cell subsets were analyzed within the CD4+ and CD8+ T-cell populations. TCMs were defined as CD45RO+ CD62L+, whereas effector memory T-cells (TEMs) were defined as CD45RO+ CD62L−.
IFN-γ secretion assays
To assess cytokine secretion, we quantified IFN-γ production with an HTRF-based human IFN-γ detection kit (Cisbio, cat. No. 62HIFNGPEG). TILs were stimulated in 96-well plates pre-coated for 2 h at 37°C with anti-CD3 (Biointron, B371202), anti-CD28 (Biointron, B371201), and anti-4-1BB (Biointron, B315002-CHO) (1 μg/mL each in DPBS). The plates were washed with DPBS before use, and TILs were cultured in X-VIVO 15 medium supplemented with 5% human AB serum at 2 × 105 cells/well for 24 h. Supernatants were collected after centrifugation (1,000 × g, 5 min) and analyzed with a Tecan SPARK microplate reader with the HTRF module. Standard curves (0–4,000 pg/mL) were generated, and sample concentrations were interpolated with 4-parameter logistic regression. The results are expressed as pg/mL.
Real-time cell analysis
Real-time cytotoxicity assays were conducted with an xCELLigence real-time cell analysis (RTCA) DP system (Agilent Technologies) to monitor T cell-mediated tumor cell killing. Tumor cell lines were obtained from the following sources: HGC-27 from Genechem (Shanghai, China), HeLa from the Chinese Academy of Sciences Cell Bank (China), and A375 from the American Type Culture Collection. All cell lines were maintained under standard culture conditions and were routinely monitored for stable morphology. No signs of mycoplasma contamination were observed. HGC-27 cells were seeded into E-Plate 16 plates at a density of 1 × 104 cells/well in RPMI-1640 medium containing 10% fetal bovine serum (FBS), whereas HeLa and A375 cells were seeded in DMEM containing 10% FBS. The cells were incubated overnight and cultured at 37°C under 5% CO2. Tumor cells were incubated for approximately 24 h, after which TILs (prepared in X-VIVO 15 medium containing 5% human AB serum) or NY-ESO-1-specific TCR-T cells were added in fresh medium at the indicated effector-to-target (E:T) ratios. For TIL assays, E:T ratios of 2:1, 4:1, and 8:1 were used. In TCR-T experiments, A375 cells were pretreated with 0 or 10 μM HCQ for 48 h before co-culture, and the killing efficacy was assessed at a 1:3 E:T ratio. Tumor cell growth and cytolysis were monitored in real time according to impedance changes, which were recorded as cell index (CI) values. Decreases in CI were interpreted as a measure of tumor cell killing. The percentage of target cell killing was calculated for each well with the following formula: % killing = [1 − (CIt/CIt0)] × 100, where CIt0 is the CI at the normalization time point set approximately 5 min before effector cell addition, and CIt is the CI at time t.
HCQ-mediated MHC-I detection in tumor cells
The human tumor cell lines A375, OVCAR-8, U-87 MG, and NCI-H2122 (all from the American Type Culture Collection) were cultured in DMEM or RPMI-1640 supplemented with 10% FBS. At 80%–90% confluence, the cells were trypsinized, seeded into 6-well plates at 3 × 105 cells/well, and cultured overnight. For drug treatment and recovery assays, cells were treated with HCQ (Shanghai Selleck, cat. No. S4430) at the specified concentrations (10 μM for A375, 15 μM for OVCAR-8 and U-87 MG, and 20 μM for NCI-H2122) for 48 h, and allowed to recover for 72 h after drug withdrawal. For programmed death-ligand 1 (PD-L1) assessment, all cell lines except OVCAR-8 were treated with vehicle (0 μM), HCQ, or recombinant human IFN-γ (3 nM; ACROBiosystems, cat. No. GMP-IFGH24) as a positive control for 48 h. The cells were then harvested and stained for flow cytometry with antibodies to HLA-ABC (BioLegend, cat. No. 311406) and PD-L1 (BioLegend, cat. No. 374514). Mean fluorescence intensity (MFI) was quantified for each marker.
Construction of NY-ESO-1-specific TCR-T cells
A codon-optimized TCR sequence (1G4-α95:LY) specific to the NY-ESO-1 peptide (SLLMWITQC) presented by HLA-A*02:01 was synthesized (General Biosystems, China). The TCR contained chimeric human/murine constant regions to enhance correct pairing, and was flanked by EcoRI and BamHI sites for cloning. The sequence was cloned into a pHAGE lentiviral vector under control of the EF1α promoter. The sequence encoded TCRα and β chains linked by a furin-SGSG-P2A self-cleaving peptide. Lentivirus was produced in 293T cells via co-transfection with the psPAX2 and pMD2.G plasmids with polyethyleneimine. Human peripheral blood mononuclear cells were activated with 300 IU/mL IL-2 and 50 ng/mL anti-CD3 (OKT3) for 48 h, then transduced with concentrated lentivirus via spinoculation (centrifugation at 1,700 × g for 100 min at 32°C). Transduced TCR-T cells were expanded in X-VIVO 15 medium with 5% human AB serum and IL-2 (100 IU/mL), and TCR expression was confirmed by flow cytometry with anti-mouse TCRβ (BioLegend, cat. No. 109208) on day 7 post-transduction. The cytotoxicity of TCR-T cells against HCQ-pretreated A375 cells was assessed with RTCA experiments.
HCQ treatment and live cell counting of expanded TILs
TILs were harvested on days 10 or 11 of the REP (REP-d10 or REP-d11), resuspended, and adjusted to a final concentration of 1.5 × 106 cells/mL. The cells were seeded in 24-well plates at 1 mL/well, then treated with HCQ at final concentrations of 0 μM, 5 μM, 7.5 μM, or 10 μM, with 5 technical replicates per condition. After 48 h incubation, live cell numbers were determined with AO/PI-based automated counting.
In vivo efficacy studies in the CRC PDX model
A patient-derived xenograft (PDX) model was established by subcutaneous implantation of fragments of human CRC into 6–8-week-old female B-NDG mice (Biocytogen, China) under specific-pathogen-free conditions. The tumor implantation day was considered D0. When the tumors reached approximately 30 mm3 (calculated as 0.5 × length × width2), the mice were assigned to separate studies comparing TIL monotherapy and combination regimens. TIL therapy was administered intravenously (i.v.). For the HCQ combination study, groups (N = 5) received either TIL monotherapy (2.36 × 107 cells/mouse, i.v., once, n = 2) or TIL plus HCQ (60 mg/kg, oral gavage, administered once 1 day before TIL infusion, n = 3). The animals were euthanized on day 9 post-treatment for tumor harvesting and analysis of MHC-I expression by flow cytometry. For the PD-1 blockade study, the study groups (N = 19) received cryoprotectant vehicle control (n = 5), TIL-only (2.36 × 107 cells/mouse, i.v., once, n = 7), or TIL plus PD-1 blockade (2 mg/kg, i.v., twice weekly for the first 2 weeks and once weekly in the third week, n = 7). The study was concluded on day 21. Mice were monitored daily for general health and clinical signs. Body weight and tumor volume were recorded three times per week. Therapeutic efficacy was evaluated with complementary approaches: tumor volume changes were monitored longitudinally to assess proliferation rates relative to the control, whereas the final antitumor activity was determined by tumor growth inhibition (TGI) based on the excised tumor weights at the study endpoint. All animal procedures were approved by the Institutional Animal Care and Use Committee of Nanchang Royo Biotech Co., Ltd. (Approval No. RYE2021102301) and were conducted in accordance with the institutional animal welfare guidelines.
Statistical analysis
All data were analyzed in GraphPad Prism 9.5.1 and SPSS 20.0. Data are presented as mean ± standard deviation (SD) or standard error of the mean (SEM). Statistical significance between two groups was assessed with unpaired t-tests or Mann–Whitney U-tests, with multiple-comparison correction when applicable. For comparisons among more than two groups, one-way or two-way ANOVA followed by Tukey’s post-hoc test was applied when assumptions of normality and homogeneity were met; otherwise, the Kruskal–Wallis test followed by Dunn’s post-hoc test was used. A P-value < 0.05 was considered statistically significant (∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, and ∗∗∗∗P < 0.0001).
Results
Less
Expansion and viability of TILs vary across tumor types during pre-REP and REP phases
TILs from MM, PC, GC, CxCa, and CRC were expanded with a two-phase protocol (Figure 1A), with success rates of 100.0% for MM (18/18) and GC (12/12), 92.3% for CxCa (12/13), and 90.0% for PC (9/10) and CRC (9/10) (Figure 1B). Only 3 cases did not expand, primarily because of small tumor specimens or low baseline TIL infiltration (Table S1). During the pre-REP phase (typically 10–14 days), representative TIL cultures achieved cell numbers exceeding 3 × 107 and viability generally above 80.0%. CxCa-derived TILs showed slower growth and initially lower viability, which gradually improved during this period (Figure 1C, D). During REP (lasting approximately 15 days), MM-derived TILs showed the highest overall expansion, approximately 2,500-fold by day 12, whereas other tumor types typically expanded less than 1,000-fold (Figure 1E). The daily expansion rate peaked between days 6 and 10 for most groups, and CxCa cultures showed a sharp increase (> 15-fold on day 7; Figure 1F). All groups showed an initial decline in viability during days 0–3, particularly CxCa, which ultimately recovered to levels > 90.0% (Figure 1G). All expanded TIL products passed predefined quality control criteria, including an absence of tumor cell contamination, negative sterility/mycoplasma testing, and an absence of tumorigenicity. Representative quality control data are not shown, but all samples met these thresholds and were cryopreserved for subsequent use.
Phenotypic diversity of expanded TILs across tumor types
Expanded TILs from all tumor types exhibited high purity, and that of CD45+CD3+ cells exceeded 93.0% on average and reached approximately 99.0% in MM and PC samples (Figure 2A). The mean proportion of CD8+ T cells among CD3+ cells markedly varied by tumor type, ranging from 43.6% in PC to 77.4% in CxCa (Figure 2A). CD39 frequency tended to be higher (approximately 68.0%) in TILs from MM, PC, and CxCa than from CRC (53.7%) and GC (45.0%). LAG-3 frequency showed moderate variability across tumor types, ranging from 37.8% in GC to 55.0% in CxCa. PD-1 levels were minimal in all groups (consistently < 0.5%; Figure 2B). Memory subset analysis indicated that both CD4+ and CD8+ TILs were dominated by TEMs (CD4+: 84.7%–96.8%; CD8+: 83.3%–93.9%), whereas TCMs were generally < 16.0% in all tumor types (Figure 2C, D). These findings indicated a consistent skewing toward an effector memory phenotype regardless of tumor origin.
In vitro antitumor cytotoxicity of TILs from various tumors
The cytotoxic activity of expanded TILs was assessed with RTCA against matched tumor cell lines: HGC-27 (GC), A375 (MM), and HeLa (CxCa). TILs induced a rapid, E:T ratio-dependent decrease in CI, and maximal cytotoxicity was observed at the highest E:T ratio (8:1). Notably, the most rapid and sustained killing was observed for HGC-27 cells, in contrast to A375 and HeLa cells (Figure S1A–C). An independent replicate with HGC-27 confirmed the reproducibility of these cytolytic dynamics (Figure S1D). Expanded TILs also secreted substantial IFN-γ levels (approximately 1.6–2.0 × 104 pg/mL) after stimulation in MM (n = 4), PC (n = 3), GC (n = 3), CxCa (n = 5), and CRC (n = 5) tumors, thus confirming their functional activities (Figure S1E).
HCQ enhances MHC-I expression and minimally affects basal PD-L1 levels in tumor cells
To investigate the immunomodulatory effects of HCQ, we treated 4 human tumor cell lines, U-87 MG (glioblastoma, n = 4), A375 (MM, n = 4), OVCAR-8 (ovarian, n = 4), and NCI-H2122 (non-small cell lung cancer, n = 4), with 10–20 μM HCQ for 48 h. Flow cytometry revealed a significant increase in surface MHC-I (HLA-ABC) expression across all cell lines after HCQ exposure (Figure 3A–D). This upregulation partially persisted after a 72-h recovery, thereby indicating a sustained effect post-treatment. We further examined whether HCQ might alter PD-L1 expression under the same conditions. The baseline PD-L1 levels were largely unaffected by HCQ treatment in all tested lines (P > 0.05; Figure 3E–G). In contrast, IFN-γ stimulation markedly upregulated PD-L1 levels (P < 0.0001), thus serving as a positive control and validating the assay’s sensitivity.
HCQ enhances early-phase cytotoxicity without compromising TIL proliferation in vitro
To assess whether HCQ might modulate tumor sensitivity to antigen-specific cytotoxicity, we pretreated A375 MM cells with 0 μM or 10 μM HCQ for 48 h before co-culture with NY-ESO-1–specific TCR-T cells. RTCA demonstrated that HCQ pretreatment resulted in a lower baseline cell index and accelerated TCR-T–mediated killing: approximately 40.0% higher killing occurred within the first 30 h than was observed in untreated targets. This enhancement diminished over time, thus yielding an overall improvement of approximately 10.0% at the endpoint (Figure S2A, B). In parallel, to evaluate whether HCQ might directly influence TIL proliferation, we treated ovarian cancer–derived TILs collected at day 12 of the REP culture with increasing HCQ concentrations (0–10 μM) for 48 h. Live cell counts increased substantially over this period at all tested concentrations (Figure S2C). Consequently, short-term HCQ exposure did not impair TIL proliferation under these conditions.
In vivo effects of combined TIL and HCQ therapy in a CRC PDX model
Building on these in vitro findings, we conducted a small-scale pilot study to evaluate the combination of TIL with HCQ in a CRC PDX model. Mice receiving TIL plus HCQ (n = 3) exhibited numerically lower tumor growth metrics (Figure S2D) and a higher mean MHC-I expression at day 9 (Figure S2E) than observed in the TIL monotherapy group (n = 2). Given the extremely small sample sizes, these differences are descriptive and cannot support definitive conclusions regarding treatment efficacy. These findings are presented to inform future study design.
Efficacy and safety of TIL combined with PD-1 blockade in a CRC PDX model
In a matched CRC PDX model, mice receiving TIL plus low-dose PD-1 blockade (2 mg/kg, n = 7) maintained significantly higher body weights than observed in the TIL-only group (n = 7, P = 0.038) and control group (n = 5, P = 0.002); moreover, no significant difference was observed between the TIL-only and control groups (P = 0.478) (Figure 4A). At the endpoint, 2 mice in the TIL-only group succumbed to cachexia before sample collection and were therefore unavailable for endpoint tumor volume measurement and tumor weight–based analyses. Among evaluable animals, tumor growth was most suppressed in the combination group (n = 7), which showed significantly smaller tumor volumes than the control group (n = 5, P = 0.002). The TIL-only group had intermediate values that did not significantly differ with respect to the control group (n = 7 initially; n = 5 at the endpoint; P > 0.05) (Figure 4C). Furthermore, the combination group showed the lowest mean tumor weights and tumor-to-body weight ratios, although intergroup differences were not statistically significant (P > 0.05) (Figure 4B, D; n = 5 for TIL-only). The TGI rates were 34.95% in the combination group vs. 22.37% in the TIL-only group (Table 1). Tumor ulceration occurred in 3 mice each in the TIL-only and control groups, but was absent in the combination group. Overall, TIL monotherapy showed moderate antitumor activity with limited durability, whereas low-dose PD-1 blockade addition correlated with significantly improved weight maintenance, superior tumor growth control, and complete prevention of tumor ulceration in this model.
Discussion
Less
Adoptive cell therapy with TILs is a promising strategy for treating solid tumors, but its broader clinical application is limited by multiple resistance mechanisms, including T-cell dysfunction and exhaustion, insufficient tumor recognition, antigen loss, and impaired T-cell trafficking31–33. Herein, we developed a novel TIL expansion platform to improve expansion consistency and generate functionally competent TILs across tumor types. A schematic overview of the optimized TIL therapy process is illustrated in Figure 5.
Traditional TIL expansion protocols commonly use high-dose IL-2 (> 3,000 IU/mL) and peripheral blood mononuclear cells as feeder cells to drive robust proliferation, and achieve approximately 1,000–5,000-fold expansion10,34,35. Because high-dose IL-2 may drive T-cell exhaustion, prior studies have suggested that low-dose IL-2 conditions might limit terminal effector differentiation and promote more functional, memory-like T cells36–38. Our feeder-free protocol with low-dose IL-2 (300–2,000 IU/mL) supported the generation of highly viable, phenotypically pure TILs from various tumor types. Single-cell and multi-omics studies have shown that tumor-specific TME variations shape T-cell composition and infiltration39–41. In our study, MM, CxCa, and CRC tumors, which are characterized by high immunogenicity and an inflamed TME20, produced CD8+-dominant TIL populations, and these are associated with enhanced antitumor efficacy42–44. In contrast, PC- and GC-derived TILs showed a wider range of CD8+ fractions among CD3+ TILs in this small cohort, in line with the immunosuppressive TMEs of these cancers, which are enriched in myeloid-derived suppressor cells and regulatory T cells45,46. Importantly, clinical studies have demonstrated that CD4+ T cells also exert strong cytotoxic activity and mediate durable clinical remission47,48. Consistent with these findings, our IFN-γ-release assays revealed that TILs from PCs and GCs retained potent antitumor function despite variable CD8+ frequencies across patients. In line with previous reports49–51, most TILs exhibited a TEM phenotype after REP. Notably, our modified pre-REP incorporating IL-7 and IL-15 supported the expansion of TILs while maintaining central memory-associated phenotypic features. Previous studies using conventional REP have reported that central memory–associated markers (e.g., CCR7) are often present at low frequencies in expanded CD3+ T cells52. Collectively, these findings suggested that our decreased IL-2, feeder-free protocol might effectively support the in vitro expansion of TILs while maintaining an effector phenotype with cytotoxic potential in different tumor types. The specific cell types involved and the therapeutic efficacy of this approach remain to be explored in future studies.
Impaired antigen presentation remains a key barrier to effective TIL therapy, and IFN-γ pretreatment of tumor cells has been used to enhance MHC-I expression, and CD8+ T cell–mediated tumor recognition and lysis53. However, IFN-γ secreted by immune cells within the TME can induce PD-L1 expression on tumor cells via JAK1/JAK2/STAT1 pathway activation54,55 and is associated with T-cell exhaustion and mutations in antigen presentation genes, thus leading to acquired resistance to immunotherapy56. HCQ, a derivative of the antimalarial drug chloroquine, inhibits autophagosome–lysosome fusion by elevating the lysosomal pH, thereby modulating autophagy22,57,58. Consequently, HCQ has demonstrated promising clinical antitumor activity59,60. By inhibiting autophagy, HCQ can restore MHC-I expression on cancer cell surfaces, and enhance antigen presentation and CD8+ T cell–mediated antitumor responses61,62. This effect, reflected by increased membrane MHC-I levels, has been demonstrated in our previous work and other studies using established methods, such as analysis of autophagy-related proteins (e.g., LC3 and p62) and measurement of autophagic flux63–66. Beyond autophagy inhibition, HCQ increases tumor cell sensitivity by promoting the accumulation of reactive oxygen species, and subsequently inducing caspase-dependent apoptosis and inhibiting TLR signaling65,67. HCQ also repolarizes M2 tumor–associated macrophages to an M1-like phenotype, increases CD8+ T–cell infiltration, and decreases immunosuppression in the TME24, thereby enhancing TIL therapy efficacy and improving clinical outcomes. Our in vitro and PDX results suggested that HCQ increases MHC-I expression without affecting PD-L1 and exerts potential combinatorial effects with TIL therapy. However, the small sample size and limited mechanistic data preclude definitive conclusions from being drawn and highlight the need for further investigation.
The PD-1/PD-L1 axis plays a central role in regulating T-cell function and shaping the TME, and its blockade has been shown in preclinical studies to restore T-cell activity and enhance the migration and function of transferred T cells at tumor sites68–70. Combining TIL therapy with PD-1 blockade has been explored as a strategy to improve the efficacy and durability of antitumor responses71,72. Pharmacodynamic studies have shown that low-dose PD-1 blockade can achieve sufficient receptor occupancy (70.0%–75.0%) for T-cell activation, thus resulting in outcomes comparable to those achieved in standard dosing26,73,74. To sustain TIL persistence while avoiding the toxicity of high-dose IL-2, we evaluated low-dose PD-1 blockade as an alternative supportive approach. In a CRC PDX model, administration of low-dose PD-1 blockade (2 mg/kg) in combination with TIL produced the most pronounced tumor control, although this finding was limited by the use of a single model. This IL-2-independent strategy has also been examined in CxCa PDX model by other groups and subsequently tested in a clinical trial in patients with advanced gynecologic cancers, using oral HCQ preconditioning and low-dose PD-1 blockade at infusion and thereafter without intravenous IL-2; early results showed favorable safety and preliminary antitumor activity29,30.
Despite these promising outcomes, this study has several limitations. The small sample size and use of a single CRC PDX model limit the generalizability of the findings. In addition, the in vitro TCR-T model used a single tumor antigen (NY-ESO-1), which might not reflect the broader antigenic heterogeneity of TILs. Moreover, because systematic and mechanistic investigations of the combined effects of HCQ and PD-1 blockade with TIL therapy were limited in our study, their precise roles in modulating TIL function and the TME remain underexplored; no post-infusion high-dose IL-2 support arm was included. Future studies should increase the sample size and validate this strategy in additional tumor models beyond CRC, to address tumor-specific differences in TIL phenotypes and functions. In addition, integrated multi-omics approaches are needed to elucidate the mechanisms underlying the potential synergy of TIL therapy with HCQ and PD-1 blockade, and to identify predictive biomarkers for clinical translation.
Conclusions
Less
We developed a feeder-free, low-dose IL-2 TIL expansion system that supports TIL therapy without post-infusion IL-2 administration in this study. Low-dose PD-1 blockade enhanced antitumor efficacy in vivo, whereas HCQ increased MHC-I expression and early T-cell cytotoxicity in vitro but showed limited in vivo efficacy, potentially because of the small sample sizes. Future studies should include expanded in vivo validation, and further investigation of the mechanisms underlying TIL persistence and TME modulation.
Funding
Less
  • This study was supported by the Science and Technology Innovation Action Plan of the Science and Technology Commission of Shanghai Municipality (STCSM) (Grant No. 22XD1432200).
References
Less
1.
Albarrán V,San Román M,Pozas J,Chamorro J,Rosero DI,Guerrero P, et al.Adoptive T cell therapy for solid tumors: current landscape and future challenges.Front Immunol. 2024; 15: 1352805.
2.
Wang S,Sun J,Chen K,Ma P,Lei Q,Xing S, et al.Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors.BMC Med. 2021; 19: 140.
3.
Julve M,Lythgoe MP,Larkin J,Furness AJS.Lifileucel: the first cellular therapy approved for solid tumours.Trends Cancer. 2024; 10: 475–7.
4.
Dudley ME,Wunderlich JR,Shelton TE,Even J,Rosenberg SA.Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients.J Immunother. 2003; 26: 332–42.
5.
Tran KQ,Zhou J,Durflinger KH,Langhan MM,Shelton TE,Wunderlich JR, et al.Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy.J Immunother. 2008; 31: 742–51.
6.
Gattinoni L,Klebanoff CA,Palmer DC,Wrzesinski C,Kerstann K,Yu Z, et al.Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.J Clin Invest. 2005; 115: 1616–26.
7.
Rosenberg SA.IL-2: the first effective immunotherapy for human cancer.J Immunol. 2014; 192: 5451–8.
8.
Chesney J,Lewis KD,Kluger H,Hamid O,Whitman E,Thomas S, et al.Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.J Immunother Cancer. 2022; 10: e005755.
9.
Dudley ME,Gross CA,Langhan MM,Garcia MR,Sherry RM,Yang JC, et al.CD8+ enriched “young” tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.Clin Cancer Res. 2010; 16: 6122–31.
10.
Itzhaki O,Hovav E,Ziporen Y,Levy D,Kubi A,Zikich D, et al.Establishment and large-scale expansion of minimally cultured “young” tumor infiltrating lymphocytes for adoptive transfer therapy.J Immunother. 2011; 34: 212–20.
11.
Boyman O,Sprent J.The role of interleukin-2 during homeostasis and activation of the immune system.Nat Rev Immunol. 2012; 12: 180–90.
12.
Liu Y,Zhou N,Zhou L,Wang J,Zhou Y,Zhang T, et al.IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor.Nat Immunol. 2021; 22: 358–69.
13.
Le HK,Graham L,Miller CHT,Kmieciak M,Manjili MH,Bear HD.Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2.Cancer Immunol Immunother. 2009; 58: 1565–76.
14.
Cha E,Graham L,Manjili MH,Bear HD.IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo.Breast Cancer Res Treat. 2010; 122: 359–69.
15.
Cieri N,Camisa B,Cocchiarella F,Forcato M,Oliveira G,Provasi E, et al.IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors.Blood. 2013; 121: 573–84.
16.
Li Y,Liu S,Hernandez J,Vence L,Hwu P,Radvanyi L.MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.J Immunol. 2010; 184: 452–65.
17.
Zhou J,Shen X,Huang J,Hodes RJ,Rosenberg SA,Robbins PF.Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.J Immunol. 2005; 175: 7046–52.
18.
Radvanyi LG,Shi Y,Vaziri H,Sharma A,Dhala R,Mills GB, et al.CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response.J Immunol. 1996; 156: 1788–98.
19.
Nijhuis EW,vd Wiel-van Kemenade E,Figdor CG,van Lier RA.Activation and expansion of tumour-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodies.Cancer Immunol Immunother. 1990; 32: 245–50.
20.
Fridman WH,Pagès F,Sautès-Fridman C,Galon J.The immune contexture in human tumours: impact on clinical outcome.Nat Rev Cancer. 2012; 12: 298–306.
21.
Mendez R,Aptsiauri N,Del Campo A,Maleno I,Cabrera T,Ruiz-Cabello F, et al.HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank.Cancer Immunol Immunother. 2009; 58: 1507–15.
22.
Yamamoto K,Venida A,Yano J,Biancur DE,Kakiuchi M,Gupta S, et al.Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I.Nature. 2020; 581: 100–5.
23.
Chude CI,Amaravadi RK.Targeting autophagy in cancer: update on clinical trials and novel inhibitors.Int J Mol Sci. 2017; 18: 1279.
24.
Li Y,Cao F,Li M,Li P,Yu Y,Xiang L, et al.Hydroxychloroquine induced lung cancer suppression by enhancing chemo-sensitization and promoting the transition of M2-TAMs to M1-like macrophages.J Exp Clin Cancer Res. 2018; 37: 259.
25.
Wang J,Fei K,Jing H,Wu Z,Wu W,Zhou S, et al.Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit.MAbs. 2019; 11: 1443–51.
26.
Brahmer JR,Drake CG,Wollner I,Powderly JD,Picus J,Sharfman WH, et al.Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.J Clin Oncol. 2010; 28: 3167–75.
27.
Zhang L,Mai W,Jiang W,Geng Q.Sintilimab: a promising anti-tumor PD-1 antibody.Front Oncol. 2020; 10: 594558.
28.
Hoy SM.Sintilimab: first global approval.Drugs. 2019; 79: 341–6.
29.
Guo J,Luo N,Ai G,Yang W,Zhu J,Li C, et al.Eradicating tumor in a recurrent cervical cancer patient with autologous tumor-infiltrating lymphocytes and a modified lymphodepleting regimen.J Immunother Cancer. 2022; 10: e003887.
30.
Guo J,Wang C,Luo N,Wu Y,Huang W,Zhu J, et al.IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer.BMC Med. 2024; 22: 207.
31.
Dafni U,Michielin O,Lluesma SM,Tsourti Z,Polydoropoulou V,Karlis D, et al.Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.Ann Oncol. 2019; 30: 1902–13.
32.
Betof Warner A,Corrie PG,Hamid O.Tumor-infiltrating lymphocyte therapy in melanoma: facts to the future.Clin Cancer Res. 2023; 29: 1835–54.
33.
Qin SS,Melucci AD,Chacon AC,Prieto PA.Adoptive T cell therapy for solid tumors: pathway to personalized standard of care.Cells. 2021; 10: 808.
34.
Besser MJ,Shapira-Frommer R,Treves AJ,Zippel D,Itzhaki O,Schallmach E, et al.Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.J Immunother. 2009; 32: 415–23.
35.
Andersen R,Donia M,Ellebaek E,Borch TH,Kongsted P,Iversen TZ, et al.Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen.Clin Cancer Res. 2016; 22: 3734–45.
36.
Besser MJ,Schallmach E,Oved K,Treves AJ,Markel G,Reiter Y, et al.Modifying interleukin-2 concentrations during culture improves function of T cells for adoptive immunotherapy.Cytotherapy. 2009; 11: 206–17.
37.
Kaartinen T,Luostarinen A,Maliniemi P,Keto J,Arvas M,Belt H, et al.Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion.Cytotherapy. 2017; 19: 689–702.
38.
Kongkaew T,Thaiwong R,Tudsamran S,Sae-Jung T,Sengprasert P,Vasuratna A, et al.TIL expansion with high dose IL-2 or low dose IL-2 with anti-CD3/anti-CD28 stimulation provides different quality of TIL-expanded T cell clones.J Immunol Methods. 2022; 503: 113229.
39.
Zheng L,Qin S,Si W,Wang A,Xing B,Gao R, et al.Pan-cancer single-cell landscape of tumor-infiltrating T cells.Science. 2021; 374: abe6474.
40.
Quek C,Pratapa A,Bai X,Al-Eryani G,Pires da Silva I,Mayer A, et al.Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy.Cell Rep. 2024; 43: 114392.
41.
Yang W,Liu S,Mao M,Gong Y,Li X,Lei T, et al.T-cell infiltration and its regulatory mechanisms in cancers: insights at single-cell resolution.J Exp Clin Cancer Res. 2024; 43: 38.
42.
Krishna S,Lowery FJ,Copeland AR,Bahadiroglu E,Mukherjee R,Jia L, et al.Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer.Science. 2020; 370: 1328–34.
43.
Besser MJ,Shapira-Frommer R,Itzhaki O,Treves AJ,Zippel DB,Levy D, et al.Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.Clin Cancer Res. 2013; 19: 4792–800.
44.
Djenidi F,Adam J,Goubar A,Durgeau A,Meurice G,de Montpréville V, et al.CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients.J Immunol. 2015; 194: 3475–86.
45.
Wang Y,Ding N,Qi L,Chen W,Wu P.Immunopharmacology of gastric cancer-deciphering immune cell subset responses and nanoparticle-mediated targeting.Front Pharmacol. 2025; 16: 1611234.
46.
Pan D,Li X,Qiao X,Wang Q.Immunosuppressive tumor microenvironment in pancreatic cancer: mechanisms and therapeutic targets.Front Immunol. 2025; 16: 1582305.
47.
Tran E,Turcotte S,Gros A,Robbins PF,Lu YC,Dudley ME, et al.Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.Science. 2014; 344: 641–5.
48.
Hunder NN,Wallen H,Cao J,Hendricks DW,Reilly JZ,Rodmyre R, et al.Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.N Engl J Med. 2008; 358: 2698–703.
49.
Amaria R,Knisely A,Vining D,Kopetz S,Overman MJ,Javle M, et al.Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.J Immunother Cancer. 2024; 12: e006822.
50.
Chiffelle J,Barras D,Pétremand R,Orcurto A,Bobisse S,Arnaud M, et al.Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma.Immunity. 2024; 57: 2466–82.e12.
51.
Borch TH,Harbst K,Rana AH,Andersen R,Martinenaite E,Kongsted P, et al.Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma.J Immunother Cancer. 2021; 9: e002703.
52.
Kverneland AH,Chamberlain CA,Borch TH,Nielsen M,Mørk SK,Kjeldsen JW, et al.Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types.J Immunother Cancer. 2021; 9: e003499.
53.
Donia M,Hansen M,Sendrup SL,Iversen TZ,Ellebæk E,Andersen MH, et al.Methods to improve adoptive T-cell therapy for melanoma: IFN-γ enhances anticancer responses of cell products for infusion.J Invest Dermatol. 2013; 133: 545–52.
54.
Knopf P,Stowbur D,Hoffmann SHL,Hermann N,Maurer A,Bucher V, et al.Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors.Mol Cancer. 2023; 22: 207.
55.
Garcia-Diaz A,Shin DS,Moreno BH,Saco J,Escuin-Ordinas H,Rodriguez GA, et al.Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression.Cell Reports. 2017; 19: 1189–201.
56.
Memon D,Schoenfeld AJ,Ye D,Fromm G,Rizvi H,Zhang X, et al.Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer.Cancer Cell. 2024; 42: 209–24.e9.
57.
Zeh HJ,Bahary N,Boone BA,Singhi AD,Miller-Ocuin JL,Normolle DP, et al.A randomized phase II preoperative study of autophagy inhibition with high-dose hydroxychloroquine and gemcitabine/nab-paclitaxel in pancreatic cancer patients.Clin Cancer Res. 2020; 26: 3126–34.
58.
Kinsey CG,Camolotto SA,Boespflug AM,Guillen KP,Foth M,Truong A, et al.Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.Nat Med. 2019; 25: 620–7.
59.
Gong C,Lin Q,Qin T,Zeng Y,Xu F,Yang Y, et al.Targeting autophagy plus high-dose CDK4/6 inhibitors in advanced HR+HER2− breast cancer: a phase 1b/2 trial.Med. 2025; 6: 100559.
60.
AlMasri SS,Zenati MS,Desilva A,Nassour I,Boone BA,Singhi AD, et al.Encouraging long-term survival following autophagy inhibition using neoadjuvant hydroxychloroquine and gemcitabine for high-risk patients with resectable pancreatic carcinoma.Cancer Med. 2021; 10: 7233–41.
61.
Agalakova NI.Chloroquine and chemotherapeutic compounds in experimental cancer treatment.Int J Mol Sci. 2024; 25: 945.
62.
Liu J,Liu X,Han Y,Zhang J,Liu D,Ma G, et al.Nanovaccine incorporated with hydroxychloroquine enhances antigen cross-presentation and promotes antitumor immune responses.ACS Appl Mater Interfaces. 2018; 10: 30983–93.
63.
Lin YC,Lin JF,Wen SI,Yang SC,Tsai TF,Chen HE, et al.Chloroquine and hydroxychloroquine inhibit bladder cancer cell growth by targeting basal autophagy and enhancing apoptosis.Kaohsiung J Med Sci. 2017; 33: 215–23.
64.
Zhang H,Wang Y,Zhu L,Qi Z,Cao K,Chang J, et al.A “bulldozer” driven by anoxic bacteria for pancreatic cancer chemo-immunotherapy.J Control Release. 2023; 360: 660–71.
65.
Peng X,Zhang S,Jiao W,Zhong Z,Yang Y,Claret FX, et al.Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy.J Exp Clin Cancer Res. 2021; 40: 374.
66.
Zhang M,Huang C,Ma X,Zhuang W,Jin H.Hydroxychloroquine increases the tumor killing efficiency via elevating the membrane MHC-I protein levels of tumor cells.Cancer Res. 2025; 85(Suppl): Abstract 5827.
67.
Ferreira PMP,de Sousa RWR,de Ferreira JRO,Militão GCG,Bezerra DP.Chloroquine and hydroxychloroquine in antitumor therapies based on autophagy-related mechanisms.Pharmacol Res. 2021; 168: 105582.
68.
Blank C,Brown I,Peterson AC,Spiotto M,Iwai Y,Honjo T, et al.PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells.Cancer Res. 2004; 64: 1140–5.
69.
Peng W,Liu C,Xu C,Lou Y,Chen J,Yang Y, et al.PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines.Cancer Res. 2012; 72: 5209–18.
70.
Fernandez-Poma SM,Salas-Benito D,Lozano T,Casares N,Riezu-Boj JI,Mancheño U, et al.Expansion of tumor-infiltrating CD8+ T cells expressing PD-1 improves the efficacy of adoptive T-cell therapy.Cancer Res. 2017; 77: 3672–84.
71.
Davies JS,Karimipour F,Zhang L,Nagarsheth N,Norberg S,Serna C, et al.Non-synergy of PD-1 blockade with T-cell therapy in solid tumors.J Immunother Cancer. 2022; 10: e004906.
72.
Hall MS,Mullinax JE,Cox CA,Hall AM,Beatty MS,Blauvelt J, et al.Combination Nivolumab, CD137 agonism, and adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic melanoma.Clin Cancer Res.2022; 28(24): 5317–29.
73.
Agrawal S,Feng Y,Roy A,Kollia G,Lestini B.Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy.J Immunother Cancer. 2016; 4: 72.
74.
Jiménez-Labaig P,Mohamed F,Tan NJI,Sanna I,El Bairi K,Khan SZ, et al.Expanding access to cancer immunotherapy: a systematic review of low-dose PD-(L)1 inhibitor strategies.Eur J Cancer. 2025; 225: 115564.
Appendix
Less
Year 2026 volume 23 Issue 6
PDF
4
2
Cite this Article
BibTeX
Article Info
doi: 10.20892/j.issn.2095-3941.2025.0441
  • Receive Date：2025-08-04
  • Online Date：2026-11-07
  • Published：2026-06-15
Article Data
Affiliations
History
  • Received：2025-08-04
  • Accepted：2025-11-04
Funding
This study was supported by the Science and Technology Innovation Action Plan of the Science and Technology Commission of Shanghai Municipality (STCSM) (Grant No. 22XD1432200).
Affiliations
    1Medical School of Chinese People’s Liberation Army (PLA) General Hospital, Beijing 100853, China
    2Senior Department of Oncology, Chinese PLA General Hospital, Beijing 100853, China
    3Shanghai Juncell Therapeutics, Shanghai 201802, China

Corresponding:

Correspondence to: Huajin Jin and Jianming Xu, E-mail: and
References
Share
https://castjournals.cast.org.cn/joweb/cbm/EN/10.20892/j.issn.2095-3941.2025.0441
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House